JP7730336B2 - 同位体標識トラピジル誘導体 - Google Patents

同位体標識トラピジル誘導体

Info

Publication number
JP7730336B2
JP7730336B2 JP2022558003A JP2022558003A JP7730336B2 JP 7730336 B2 JP7730336 B2 JP 7730336B2 JP 2022558003 A JP2022558003 A JP 2022558003A JP 2022558003 A JP2022558003 A JP 2022558003A JP 7730336 B2 JP7730336 B2 JP 7730336B2
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound
solvate
acceptable salt
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022558003A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519289A (ja
JP2023519289A5 (https=
Inventor
ボードバー，アーラッシュ
マサムネ，ヒロコ
エス． ウェイド，ウォーレン
Original Assignee
シノピア バイオサイエンシーズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シノピア バイオサイエンシーズ，インク． filed Critical シノピア バイオサイエンシーズ，インク．
Publication of JP2023519289A publication Critical patent/JP2023519289A/ja
Publication of JP2023519289A5 publication Critical patent/JP2023519289A5/ja
Priority to JP2025135217A priority Critical patent/JP2025183224A/ja
Application granted granted Critical
Publication of JP7730336B2 publication Critical patent/JP7730336B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022558003A 2020-03-26 2021-03-25 同位体標識トラピジル誘導体 Active JP7730336B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025135217A JP2025183224A (ja) 2020-03-26 2025-08-14 同位体標識トラピジル誘導体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063000347P 2020-03-26 2020-03-26
US63/000,347 2020-03-26
US202063063846P 2020-08-10 2020-08-10
US63/063,846 2020-08-10
PCT/US2021/024226 WO2021195425A1 (en) 2020-03-26 2021-03-25 Isotopically-labelled trapidil derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025135217A Division JP2025183224A (ja) 2020-03-26 2025-08-14 同位体標識トラピジル誘導体

Publications (3)

Publication Number Publication Date
JP2023519289A JP2023519289A (ja) 2023-05-10
JP2023519289A5 JP2023519289A5 (https=) 2024-04-01
JP7730336B2 true JP7730336B2 (ja) 2025-08-27

Family

ID=77892379

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022558003A Active JP7730336B2 (ja) 2020-03-26 2021-03-25 同位体標識トラピジル誘導体
JP2025135217A Pending JP2025183224A (ja) 2020-03-26 2025-08-14 同位体標識トラピジル誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025135217A Pending JP2025183224A (ja) 2020-03-26 2025-08-14 同位体標識トラピジル誘導体

Country Status (10)

Country Link
US (1) US12508267B2 (https=)
EP (1) EP4125853A4 (https=)
JP (2) JP7730336B2 (https=)
KR (1) KR20230013023A (https=)
CN (3) CN116496279B (https=)
AU (1) AU2021244241A1 (https=)
CA (1) CA3177066A1 (https=)
IL (1) IL296788A (https=)
MX (1) MX2022011879A (https=)
WO (1) WO2021195425A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7049683B2 (ja) 2016-04-04 2022-04-07 シノピア バイオサイエンシーズ，インク． トラピジルを使用する錐体外路症候群の処置
MX2022011879A (es) * 2020-03-26 2023-01-11 Sinopia Biosciences Inc Derivados de trapidilo marcados isotopicamente.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019510826A (ja) 2016-04-04 2019-04-18 シノピア バイオサイエンシーズ，インク． トラピジルを使用する錐体外路症候群の処置

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4739044A (en) 1985-06-13 1988-04-19 Amgen Method for derivitization of polynucleotides
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IT1222414B (it) 1987-07-31 1990-09-05 Chiesi Farma Spa Composizioni farmaceutiche contenenti trapidil,loro procedimento di preparazione e relaticvo impiego terapeutico
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
US5994056A (en) 1991-05-02 1999-11-30 Roche Molecular Systems, Inc. Homogeneous methods for nucleic acid amplification and detection
US5770358A (en) 1991-09-18 1998-06-23 Affymax Technologies N.V. Tagged synthetic oligomer libraries
JP3195391B2 (ja) 1991-11-14 2001-08-06 エスエス製薬株式会社 徐放性トラピジル錠
HU227530B1 (en) 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
CA2124087C (en) 1991-11-22 2002-10-01 James L. Winkler Combinatorial strategies for polymer synthesis
US6033854A (en) 1991-12-16 2000-03-07 Biotronics Corporation Quantitative PCR using blocking oligonucleotides
US5348853A (en) 1991-12-16 1994-09-20 Biotronics Corporation Method for reducing non-specific priming in DNA amplification
US5567583A (en) 1991-12-16 1996-10-22 Biotronics Corporation Methods for reducing non-specific priming in DNA detection
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
JP2616252B2 (ja) 1992-10-16 1997-06-04 日本新薬株式会社 ワックスマトリックスの製法
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
ES2293638T3 (es) * 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
DE19514048A1 (de) 1995-04-13 1996-10-17 Rentschler Arzneimittel Trapidil zur Verwendung in der Therapie von immunmodulatorisch beeinflußbaren Krankheitsbildern
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5869717A (en) 1997-09-17 1999-02-09 Uop Llc Process for inhibiting the polymerization of vinyl aromatics
DE69829402T2 (de) 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Expressionsprofile in adulten und fötalen organen
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
JP2001322933A (ja) 2000-05-15 2001-11-20 Ucb Sa Ｃｄ４０シグナル遮断剤
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
WO2005007096A2 (en) 2003-07-11 2005-01-27 Merck & Co., Inc. Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
US20080242657A1 (en) 2004-03-26 2008-10-02 Marino Michael J Treatment of Tremor with Histamine H3 Inverse Agonists or Hist Amine H3 Antagonists
CN101360421B (zh) 2005-11-18 2014-06-18 康乃尔研究基金会有限公司 烟酰核苷组合物及其使用方法
KR20100019470A (ko) * 2007-04-30 2010-02-18 아보트 러보러터리즈 디아실글리세롤 ｏ-아실트랜스퍼라제 타입 １ 효소의 억제제
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
WO2009129537A2 (en) 2008-04-18 2009-10-22 Gary Zabow Magnetic microstructures for magnetic resonance imaging
KR102759126B1 (ko) 2010-12-30 2025-01-24 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
KR101534395B1 (ko) 2013-08-01 2015-07-09 서울대학교산학협력단 트라피딜을 유효성분으로 포함하는 골 관련 질환의 예방 또는 치료용 조성물
WO2017059118A1 (en) 2015-09-29 2017-04-06 Duke University Compositions and methods for identifying and treating dystonia disorders
US11281170B2 (en) 2015-12-29 2022-03-22 Jones And Malterer Technology Innovations Incorporated Multi-point synchronizable and scalable lighting control systems
MX2020007994A (es) * 2018-02-02 2020-09-09 Boehringer Ingelheim Int Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat).
CA3163242A1 (en) 2019-12-02 2021-06-10 Aarash BORDBAR Treating cognitive disorders using trapidil
MX2022011879A (es) 2020-03-26 2023-01-11 Sinopia Biosciences Inc Derivados de trapidilo marcados isotopicamente.
US20230242538A1 (en) 2020-06-24 2023-08-03 Yale University PanK Modulators and Methods Using Same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019510826A (ja) 2016-04-04 2019-04-18 シノピア バイオサイエンシーズ，インク． トラピジルを使用する錐体外路症候群の処置

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BORNSCHEIN, I. et al.，Biotransformation von Trapidil，Pharmazie，1978年，Vol.33，pp.51-63
HARDER, S. et al.，Pharmacokinetics of trapidil, an antagonist of platelet derived growth factor, in healthy subjects and in patients with liver cirrhosis，British Journal of Clinical Pharmacology，1996年，Vol.42，pp.443-449

Also Published As

Publication number Publication date
TW202202502A (zh) 2022-01-16
CN116496279B (zh) 2025-12-12
CN116496279A (zh) 2023-07-28
EP4125853A1 (en) 2023-02-08
AU2021244241A1 (en) 2022-11-24
KR20230013023A (ko) 2023-01-26
US20230102580A1 (en) 2023-03-30
JP2023519289A (ja) 2023-05-10
JP2025183224A (ja) 2025-12-16
TW202547838A (zh) 2025-12-16
WO2021195425A1 (en) 2021-09-30
IL296788A (en) 2022-11-01
CN115916180A (zh) 2023-04-04
CA3177066A1 (en) 2021-09-30
EP4125853A4 (en) 2024-07-03
CN121550230A (zh) 2026-02-24
US12508267B2 (en) 2025-12-30
MX2022011879A (es) 2023-01-11

Similar Documents

Publication Publication Date Title
JP2025183224A (ja) 同位体標識トラピジル誘導体
US11643390B2 (en) Synthesis of N,N-dimethyltryptamine-type compounds, methods, and uses
CN115403626A (zh) 新结晶形式
KR20140008297A (ko) 도파민성 안정제로서 유용한 프리도피딘의 듀테륨화된 유사체
CN101945876B (zh) 对慢性疼痛疾病有活性的含氮双环化合物
JP2015528020A (ja) 重水素化イブルチニブ
JP2016512831A (ja) 重水素化されたパルボシクリブ
JP2016505015A (ja) 重水素化モメロチニブ（ｍｏｍｅｌｏｔｉｎｉｂ）
WO2018200605A1 (en) Use of valbenazine for treating levodopa-induced dyskinesia
AU2019256722A1 (en) Imidazopyridines useful as mitochondrial uncouplers
JPS62120317A (ja) 痴呆症状改善・治療剤
EP3630115A1 (en) Compositions and methods for preparing and using mitochondrial uncouplers
JP2025514548A (ja) カレバスチンの塩及びその用途
JP2018530612A (ja) パーキンソン病の治療のための重水素化レボドパとカルビドパおよびオピカポンとの組合せ
TWI917367B (zh) 經同位素標記之曲匹地（ｔｒａｐｉｄｉｌ）衍生物及其醫藥組合物與用途
TWI918457B (zh) 經同位素標記之曲匹地(trapidil)衍生物
JPH0269417A (ja) 精神分裂病治療用組成物
HK40090744A (zh) 同位素标记的曲匹地尔衍生物
AU2018352215A1 (en) Combination therapy for preventing addiction
JP2022515156A (ja) ボリナンセリンの重水素化形態および誘導体
JP2016512530A (ja) 重水素化されたパクリチニブ
JPH08176129A (ja) １−（アリールアルケニル）−４−（アリールメチル）ピペラジン構造を有する新規化合物、その製造方法及びそれを含有する薬学的組成物
WO2024261234A1 (en) Deuterated analogs of sirtuin 6 modulator imu-856
CN119896673A (zh) Glp-1r激动剂与二甲双胍在制备治疗糖尿病及其并发症药物中的应用
KR20260046467A (ko) Idh1 억제제의 공결정, 그의 제조 방법, 그의 제약 조성물, 및 그를 수반하는 치료 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250722

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250815

R150 Certificate of patent or registration of utility model

Ref document number: 7730336

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150